Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature.

Atif M, Azeem M, Sarwar MR.

Springerplus. 2016 Feb 25;5:182. doi: 10.1186/s40064-016-1824-2. eCollection 2016. Review.

2.

The introduction of generic risperidone in Medicare Part D.

Fung V, Price M, Busch AB, Landrum MB, Fireman B, Nierenberg AA, Newhouse JP, Hsu J.

Am J Manag Care. 2016 Jan;22(1):41-8.

3.

Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model.

Zuluaga AF, Rodriguez CA, Agudelo M, Vesga O.

BMC Res Notes. 2015 Oct 7;8:546. doi: 10.1186/s13104-015-1507-z.

4.

Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder.

Khoonsari H, Oghazian MB, Kargar M, Moin M, Khalili H, Alimadadi A, Torkamandi H, Ghaeli P.

Iran J Psychiatry Behav Sci. 2015 Jun;9(2):e230. doi: 10.17795/ijpbs230. Epub 2015 Jun 23.

5.

Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis.

Molnar AO, Fergusson D, Tsampalieros AK, Bennett A, Fergusson N, Ramsay T, Knoll GA.

BMJ. 2015 Jun 22;350:h3163. doi: 10.1136/bmj.h3163. Review.

6.

Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjects.

Lee SY, Kim JR, Jung JA, Huh W, Bahng MY, Ko JW.

Drug Des Devel Ther. 2015 Jun 2;9:2811-7. doi: 10.2147/DDDT.S82820. eCollection 2015.

7.

Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide.

Tamargo J, Le Heuzey JY, Mabo P.

Eur J Clin Pharmacol. 2015 May;71(5):549-67. doi: 10.1007/s00228-015-1832-0. Epub 2015 Apr 15. Review.

8.

A critical review of brand and generic alendronate for the treatment of osteoporosis.

Brown JP, Davison KS, Olszynski WP, Beattie KA, Adachi JD.

Springerplus. 2013 Oct 21;2:550. doi: 10.1186/2193-1801-2-550. eCollection 2013. Review.

9.

Study on requirements of bioequivalence for registration of pharmaceutical products in USA, Europe and Canada.

Galgatte UC, Jamdade VR, Aute PP, Chaudhari PD.

Saudi Pharm J. 2014 Nov;22(5):391-402. doi: 10.1016/j.jsps.2013.05.001. Epub 2013 May 31. Review.

10.

Patient-reported outcomes of therapy with two brands of ibuprofen.

Nwidu LL, Eniojukan JF, Oparah AC.

Pharm Pract (Granada). 2008 Jul;6(3):136-41. Epub 2008 Sep 15.

11.

Sampling times and genotyping concerns in bioequivalence evaluation of branded and generic formulations.

Zhao XY, Xu HM, Zhou Q.

Ther Clin Risk Manag. 2013;9:463-8. doi: 10.2147/TCRM.S54607. Epub 2013 Nov 25. No abstract available.

12.

Evaluation and comparison of in-vitro dissolution profiles for different brands of amoxicillin capsules.

Kassaye L, Genete G.

Afr Health Sci. 2013 Jun;13(2):369-75. doi: 10.4314/ahs.v13i2.25.

14.
15.

Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers.

Tacca MD, Pasqualetti G, Gori G, Pepe P, Di Paolo A, Lastella M, De Negri F, Blandizzi C.

Ther Clin Risk Manag. 2013;9:303-11. doi: 10.2147/TCRM.S39024. Epub 2013 Jul 24.

16.

Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.

Gasser UE, Fischer A, Timmermans JP, Arnet I.

BMC Pharmacol Toxicol. 2013 Apr 23;14:24. doi: 10.1186/2050-6511-14-24.

17.

Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.

Hartung DM, Middleton L, Svoboda L, McGregor JC.

CNS Drugs. 2012 Aug 1;26(8):707-16. doi: 10.2165/11634260-000000000-00000.

18.

Generic antibiotic industries: Challenges and implied strategies with regulatory perspectives.

Venkatesh M, Bairavi VG, Sasikumar KC.

J Pharm Bioallied Sci. 2011 Jan;3(1):101-8. doi: 10.4103/0975-7406.76481.

19.

In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin.

Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O.

BMC Infect Dis. 2010 Jun 4;10:153. doi: 10.1186/1471-2334-10-153.

20.

Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model.

Zuluaga AF, Agudelo M, Cardeño JJ, Rodriguez CA, Vesga O.

PLoS One. 2010 May 20;5(5):e10744. doi: 10.1371/journal.pone.0010744.

Items per page

Supplemental Content

Write to the Help Desk